CannTrust™ Announces Receiving Health Canada Approval to Export Medical Marijuana Internationally and the Shipping of Medical Marijuana to Australia
VAUGHAN, ON, Nov. 8, 2017 /CNW/ – CannTrust Holdings Inc. (“CannTrust” or the “Company” I CSE: TRST), a licensed producer of medical cannabis under the Health Canada Access to Cannabis for Medical Purposes Regulation (” ACMPR “) program, is pleased to announce that it has received Health Canada approval to export medical marijuana internationally to Countries where medical marijuana is legalized and that the Company has now begun shipping to Australia.
We are very proud and excited to begin the international shipping of our pharmaceutically standardized medical marijuana products. Australia is the first of many markets that we are expecting to supply. Other countries that we anticipate shipping to shortly are Germany, Denmark and Brazil.
Brad Rogers, President of CannTrust Inc.
Rogers continued “Germany has implemented one of the most progressive medical marijuana Plans whereby marijuana will be distributed via Pharmacies with Insurers required to cover the costs just as they do for Pharmaceutical drugs. CannTrust is an experienced and advanced Licensed Producer of Pharmaceutical grade cannabis in Canada and our recently completed Phase 1 of our 430,000 square feet Niagara Facility, is perfectly timed in order for us to supply the orders we have received. The pending legislation to legalize the adult consumer recreational use of cannabis provides a further major opportunity for the Company. With the completion of all phases of our Niagara expansion we plan to have in excess of 1,000,000 square feet of production capacity. This will give us the ability to acquire a substantial share of the increased demand arising from these new markets.”
Our plan was always to be a Pharmaceutical Company producing quality medical cannabis in a variety of unique dosage forms that will provide the best treatment options for patients. Our shipments to Australia are just the beginning of what we believe will be a World market opportunity for us along with our exclusive global pharma manufacturing partner, Apotex Inc., for our Canadian made, pharmaceutically standardized, cannabis products.
Company CEO Eric Paul, a veteran Pharmacist
Since its inception in 2014, CannTrust has led the Canadian market in producing pharmaceutically standardized product.
As a federally regulated licensed producer, CannTrust™ brings more than 40 years of pharmacy and healthcare experience to the medical cannabis industry. CannTrust currently operates a 50,000 square foot state-of-the-art hydroponic facility in Vaughan, Ontario and with this recently received Health Canada Cultivation License has begun production at Phase 1 of its 430,000 square foot cultivation facility in the Niagara region.
CannTrust™ is committed to research and innovation, as well as contributing to the growing body of evidence- based research regarding the use and efficacy of cannabis. Our product development teams along with our exclusive global pharma partner, Apotex Inc., are diligently innovating and developing products that will make it easier for patients to use medical cannabis. We support ongoing patient education about medical cannabis and have launched a compassionate use program to support patients with financial needs.
Get ahead of the crowd by signing up for 420 Investor, the largest & most comprehensive premium subscription service for cannabis traders and investors since 2013.